Seagen Aims To Make Tukysa First Drug For HER2-Positive Colorectal Cancer

 
• By Jessica Merrill
  
number one
Seagen hopes to be first to market with a HER2-targeted treatment for colorectal cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D